Aligos Therapeutics (NASDAQ:ALGS) Releases Earnings Results, Beats Estimates By $0.95 EPS

Aligos Therapeutics (NASDAQ:ALGS) issued its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.95, FiscalAI reports. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The firm had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million.

Aligos Therapeutics Stock Performance

ALGS traded up $0.08 on Friday, hitting $5.59. The company had a trading volume of 335,793 shares, compared to its average volume of 160,467. The stock has a market capitalization of $34.60 million, a price-to-earnings ratio of -0.64 and a beta of 2.31. The stock has a fifty day moving average price of $5.33 and a 200-day moving average price of $6.43. Aligos Therapeutics has a 12-month low of $3.98 and a 12-month high of $13.69.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Verition Fund Management LLC purchased a new position in Aligos Therapeutics during the fourth quarter valued at approximately $664,000. Renaissance Technologies LLC increased its holdings in shares of Aligos Therapeutics by 55.3% during the 4th quarter. Renaissance Technologies LLC now owns 85,444 shares of the company’s stock valued at $796,000 after purchasing an additional 30,425 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Aligos Therapeutics by 19.7% in the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock valued at $615,000 after purchasing an additional 10,880 shares during the period. Two Sigma Investments LP boosted its holdings in Aligos Therapeutics by 223.0% during the third quarter. Two Sigma Investments LP now owns 38,995 shares of the company’s stock worth $382,000 after buying an additional 26,922 shares in the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Aligos Therapeutics by 64.0% in the third quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock valued at $299,000 after buying an additional 11,904 shares in the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Weiss Ratings cut Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Lake Street Capital initiated coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target for the company. Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.50.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.